AgiosMedical
@AgiosMedical
Dedicated to communicating emerging, trusted scientific information to healthcare professionals (HCPs). For US HCPs only. http://agios.com/agma/
Welcome to the official Twitter page for Agios Medical Affairs. Here, we’ll be communicating our scientific information and latest developments in #RareDisease and #Hematology for HCPs. Not intended to provide medical advice. #AgiosMedical
Attend the sponsored symposium at the 1st TIF Pan-American Conference on Thalassemia and Other Haemoglobin Disorders and 2nd RAIN Summit hosted by @thalassaemiaTIF & @cooleysanemia. Access #Thalassemia resources: bit.ly/3Fyj9qs #AgiosMedical #TIF2025
Read the new publication by @drKMusallam (Khaled Musallam) et al., “Lifetime Risk of Liver Disease in Patients With β-Thalassemia: Data From the de-LIGHT Retrospective Cohort Study” in the European Journal of Haematology here: bit.ly/4lAMlMU Thalassemia #AgiosMedical
Read the new publication by @CaptainAV (Kevin Kuo) et al., "Long-term efficacy and safety of mitapivat in non-transfusion-dependent α- or β-thalassemia: An open label phase 2 study" published in @BrJHaem (British Journal of Haematology): bit.ly/44JRmx9 #AgiosMedical

We’re at #EHA2025 (booth # C04), connecting with the #hematology community and our partners to explore the latest research and share the progress of our pyruvate kinase activation portfolio in rare blood disorders. Learn more about our presence at the meeting:…
Couldn’t attend #EHA2025? Check out recent data presented across #Thalassemia, #SickleCell disease, #PKDeficiency, and #MDS. See the research here: bit.ly/3ZupREX #AgiosMedical
Interested in learning more about our commitment to advancing rare diseases and hematology? Submit an inquiry to our expert Medical Science Liaison (MSL) team today: bit.ly/3XutEly #EHA2025 #AgiosMedical
Attend our #EHA2025 presentations and read our publications to learn about our science and advancements in rare anemias. Get more details here: bit.ly/43D6Sur #AgiosMedical
Attend our #EHA2025 presentations and read our publications to learn about our science and advancements in rare anemias. Get more details here: bit.ly/3HveAhm #AgiosMedical
Stop by booth #C04 at #EHA2025 to meet our #AgiosMedical team and explore our recent data and clinical insights on #Thalassemia, #SickleCell, #PKDeficiency, and #MDS. See what we’re up to at EHA: bit.ly/3HveAhm #AgiosMedical
We’re looking forward to presenting recent data in pyruvate kinase activation in #SickleCell disease at the Foundation for Sickle Cell Disease Research (@FundSickleCell) Annual Educational Symposium & Scientific Meeting. Explore our sickle cell disease resources:…

We’re looking forward to connecting with the hematology community at #EHA2025. Join us as we present the latest data across rare anemias including #Thalassemia, #SickleCell disease, #PKDeficiency, and #MDS: bit.ly/4jx7ypL #AgiosMedical
We’re excited to return to #EHA2025 to connect with the #hematology community and share our clinical results and scientific insights, highlighting the potential of our pyruvate kinase (PK) activation portfolio in treating rare blood disorders. Read more: bit.ly/4j6hYw9
International Thalassaemia Day is a day dedicated to come together across the medical community and raise awareness. We proudly embrace this year’s theme, "Together for Thalassaemia: Uniting Communities, Prioritizing Patients” and honor the community. Access our #thalassemia…

Stay informed about the latest developments in #Thalassemia by reading our latest quarterly newsletter, ThalassemiaNEWS, highlighting International Thalassaemia Day: bit.ly/44n6jpe #InternationalThalassaemiaDay #ITD2025 #AgiosMedical
We’re honoring Pyruvate Kinase Deficiency Day through our relentless dedication to scientific breakthroughs and commitment to the patient community. Learn more about #PKDeficiency: bit.ly/4jsOJot #AgiosMedical #PKDeficiencyDay
🚨 In this editorial, authors provide essential context behind these updated TIF #Guidelines, highlighting key recommendations Top tip: 🔎 Don’t forget to check the supplementary Appendix for a concise summary of monitoring standards. @thalassaemiaTIF 👉bit.ly/43N1Ewn
People with #Thalassemia may face a higher rate of complications, underscoring the need for specialized care. Read our Thalassemia Burden of Disease resource to learn about these complications: bit.ly/3XJx8At #AgiosMedical
See the latest translations of the #Thalassemia Fast Facts for healthcare providers and patients here: bit.ly/3XJx8At Follow for more updates on thalassemia resources. #AgiosMedical
#AgiosNews: Our ACTIVATE-Kids Phase 3 study of our late-stage pyruvate kinase (PK) activator in children aged 1 to <18 years with PK deficiency who are not regularly transfused achieved its primary endpoint. This is the first study to demonstrate efficacy of an oral therapy for…
Looking for more #Thalassemia resources? @thalassemiaTIF released the 5th edition of the Guidelines for the Management of Transfusion Dependent β-Thalassemia. 17 chapters, authored by global experts, cover diagnosis, management, pathophysiology, and new clinical insights to…
